Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors-Reference-Cited by-同舟云学术

Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors

Published:2020-05-21 Issue:8 Volume:23 Page:894-901
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Lin Huamao M.¹^ORCID,Pan Xiaoyun¹,Hou Peijie¹,Huang Hui¹,Wu Yanyu¹,Ren Kaili¹,Jahanzeb Mohammad²

Affiliation:

1. Global Outcomes Research, Millennium Pharmaceuticals, Inc. (A wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, MA, USA;

2. Florida Precision Oncology, a division of 21st Century Oncology, Boca Raton, FL, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2020.1762620

Reference36 articles.

1. Non-small cell lung cancer: current treatment and future advances

2. ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

3. TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS

4. EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

5. Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?;Expert Opinion on Therapeutic Targets;2024-08-19

2. Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib;JTO Clinical and Research Reports;2024-03

3. Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer;Frontiers in Public Health;2024-02-15

4. Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer Patients;Cancers;2024-01-30

5. Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country;Cancer Management and Research;2023-01